<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01861561</url>
  </required_header>
  <id_info>
    <org_study_id>125/2556(EC2)</org_study_id>
    <nct_id>NCT01861561</nct_id>
  </id_info>
  <brief_title>Low-dose VS High-dose IV Cyclophosphamide for Proliferative LN in Children</brief_title>
  <acronym>Low/highIVCY</acronym>
  <official_title>Efficacy and Infectious Complications of Induction Therapy With Low-dose Versus High-dose Intravenous Cyclophosphamide for Proliferative Lupus Nephritis in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Proliferative lupus nephritis (LN)is the predominant cause of morbidity and mortality in
      juvenile Systemic Lupus Erythematosus (SLE). Induction therapy with high-dose intravenous
      cyclophosphamide can improve renal outcomes, but considerably associated with infection.
      Although severe infection is the significant complication related to poorer prognosis for
      juvenile SLE patients in Asia, cyclophosphamide is still commonly used as the drug of choice
      for severe lupus nephritis. Euro-Lupus Nephritis Trial demonstrated low-dose intravenous
      cyclophosphamide regimen followed by azathioprine achieved good clinical results comparable
      with obtained high-dose regimen. There was lower number of severe infection episodes, but no
      significant difference. Recent studies applied low dose of cyclophosphamide (500 mg/m2/dose
      or 500 mg/dose)in young patients and showed good renal response. Low-dose intravenous
      cyclophosphamide regimen might promote non-inferior renal remission whereas decrease risk of
      serious infection and improve overall patient outcomes.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>renal response</measure>
    <time_frame>at 6 months of the treatment</time_frame>
    <description>3 main renal parameters: renal function(eCCl),proteinuria(spot urine protein/creatinine ratio, UPCR), and urine sediment (rbc,wbc,and casts) 'renal remission'
complete- normal renal function, UPCR&lt;0.2, and normal urine sediment(rbc&lt;5,wbc&lt;5/HPF,and no cast)
partial- at least 50%improvement in 2 main parameters with UPCR &lt;= 1.0 and without worsening of remaining main parameter</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>infection</measure>
    <time_frame>within 6 months</time_frame>
    <description>infectious episode classified in 3 levels
mild infection - the infection that is not serious and the patient could be treated with oral antimicrobial agent in outpatient clinic
moderate infection - the infection that the patient need admission or intravenous antimicrobial agent
serious infection - the infection that the patient is critically ill and need ICU care</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Patient well being</measure>
    <time_frame>at 0,1,3 and 6 months of the treatment</time_frame>
    <description>using visual analogue scale (VAS 0-10)for self assessment their well being</description>
  </other_outcome>
  <other_outcome>
    <measure>SLE disease activity index score</measure>
    <time_frame>at 0,1,3 and 6 months of the treatment</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Renal Insufficiency</condition>
  <condition>Infection</condition>
  <arm_group>
    <arm_group_label>Low-dose intravenous cyclophosphamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low-dose intravenous cyclophosphamide 500 mg/m2/dose every 4 weeks/months for 7 doses. Total duration is 6 months for the induction treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-dose intravenous cyclophosphamide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>High-dose intravenous cyclophosphamide 1,000 mg/m2/dose, the first dose will be started with 500 mg/m2/dose and steped up to 750 mg/m2/dose for the second dose. Then the dosage will be increased to 1,000 mg/m2/dose for the third dose and continued the dosage through the seventh dose. Total duration is 6 months for the induction treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low-dose intravenous cyclophosphamide</intervention_name>
    <description>Intravenous cyclophosphamide 500 mg/m2/dose every 4 weeks/months, total 7 doses</description>
    <arm_group_label>Low-dose intravenous cyclophosphamide</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High-dose intravenous cyclophosphamide</intervention_name>
    <description>Intravenous cyclophosphamide every 4 weeks/months, total in 7 doses:
the 1st dose-500 mg/m2/dose,the 2nd dose-750 mg/m2/dose, the 3rd-7th doses- 1,000 mg/m2/dose with the maximum dose at 1,500 mg/dose</description>
    <arm_group_label>High-dose intravenous cyclophosphamide</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Child up to 15 years of age who fulfilled the 1997 updating the American College of
             Rheumatology revised criteria for the classification of SLE and his or her renal
             biopsy reveals lupus nephritis class III or IV regarding to International Society of
             Nephrology/Renal Pathology Society revision on the classification of the lupus
             nephritis.

        Exclusion Criteria:

          -  patient who has prior renal insufficiency due to chronic kidney disease other than
             lupus nephritis

          -  patient who has the history of cyclophosphamide hypersensitivity

          -  patient who has prior cyclophosphamide or mycophenolate mofetil administration within
             6 months

          -  patient who is pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nuntawan Piyaphanee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Siriraj Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anirut Pattaragarn, MD</last_name>
    <role>Study Director</role>
    <affiliation>Siriraj Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nuntawan Piyaphanee, MD</last_name>
    <phone>+662-419-7000</phone>
    <phone_ext>5660</phone_ext>
    <email>nuntawan.piy@mahidol.ac.th</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nephrology division, Department of Pediatrics, Siriraj Hospital</name>
      <address>
        <city>Bangkoknoi</city>
        <state>Bangkok</state>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nuntawan Piyaphanee, MD</last_name>
      <phone>+662-419-7000</phone>
      <phone_ext>5660</phone_ext>
      <email>nuntawan.piy@mahidol.ac.th</email>
    </contact>
    <contact_backup>
      <last_name>Anirut Pattaragarn, MD</last_name>
      <phone>+662-419-7000</phone>
      <phone_ext>5660</phone_ext>
      <email>Apattaragarn@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Nuntawan Piyaphanee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anirut Pattaragarn, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Achra Sumboonnanonda, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Suroj Supavekin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kraisoon Lomjansook, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2013</study_first_submitted>
  <study_first_submitted_qc>May 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2013</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

